• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·BIOFILCHEM.NS
Share

Biofil Chemicals and Pharmaceuticals Limited Stocks

₹ 32.82Last Updated 27.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 5.41M

₹ 32.82
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Biofil Chemicals and Pharmaceuticals Limited, headquartered in Indore, India, is primarily involved in the country's pharmaceutical and chemical industries. This company supplies a comprehensive array of fundamental drugs and chemical compounds, including sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and dicyclomine hydrochloride. Additionally, its product line features plastic dippers and caps. Beyond its product offerings, Biofil also provides contract manufacturing services for pharmaceutical items. The company was founded in 1985.

Company Valuation

Slightly undervalued
5/7

Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.07.2026 08:00

Europe's richest man regrets selling his Netflix and Google shares too early

29.07.2026 08:00

Ford Raises Profit Forecast for the Second Time This Year: Are the Aluminum Problems Behind It?

29.07.2026 04:16

The U.S. announced that it had intercepted Iranian missiles. Oil prices surged 4%, halting their decline

29.07.2026 02:06

The U.S. has restricted imports of humanoid robots. Which companies will be affected by this?

29.07.2026 01:14

July Could Be the Worst Month for Chipmakers' Stocks Since the Dot-Com Era

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026